Free Trial

DENTSPLY SIRONA (NASDAQ:XRAY) Sets New 52-Week Low - Time to Sell?

DENTSPLY SIRONA logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • DENTSPLY SIRONA shares fell to a new 52-week low of $8.38, trading below both their 50-day and 200-day moving averages amid ongoing weakness.
  • Analyst sentiment is cautious: the stock has an average rating of “Hold”, with three Buy, seven Hold and three Sell ratings, and an average price target of $12.92.
  • The company beat quarterly earnings and revenue expectations, but revenue declined 4.1% year over year and the firm posted a negative net margin; institutional investors nevertheless own approximately 95.7% of the shares.
  • MarketBeat previews the top five stocks to own by November 1st.

DENTSPLY SIRONA Inc. (NASDAQ:XRAY - Get Free Report)'s share price hit a new 52-week low during mid-day trading on Wednesday. The stock traded as low as $8.38 and last traded at $8.3360, with a volume of 1,107,926 shares trading hands. The stock had previously closed at $8.51.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on XRAY shares. Weiss Ratings reissued a "sell (e+)" rating on shares of DENTSPLY SIRONA in a research report on Monday, August 3rd. Barclays lifted their price target on shares of DENTSPLY SIRONA from $9.00 to $11.00 and gave the stock an "underweight" rating in a report on Monday, August 24th. Barrington Research set a $15.00 price target on shares of DENTSPLY SIRONA in a report on Monday, August 10th. Piper Sandler dropped their price objective on DENTSPLY SIRONA from $14.00 to $12.00 and set a "neutral" rating on the stock in a research note on Friday, October 9th. Finally, BMO Capital Markets reduced their price objective on DENTSPLY SIRONA from $13.00 to $10.00 and set a "market perform" rating for the company in a report on Thursday, September 17th. Three research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and three have given a Sell rating to the company's stock. According to MarketBeat.com, DENTSPLY SIRONA currently has an average rating of "Hold" and an average price target of $12.92.

View Our Latest Stock Report on XRAY

DENTSPLY SIRONA Trading Down 0.9%

The stock has a market cap of $1.68 billion, a PE ratio of -3.07, a P/E/G ratio of 1.09 and a beta of 0.87. The firm has a 50-day simple moving average of $10.38 and a 200-day simple moving average of $11.09. The company has a quick ratio of 1.07, a current ratio of 1.63 and a debt-to-equity ratio of 1.48.

DENTSPLY SIRONA (NASDAQ:XRAY - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.35 by $0.17. The company had revenue of $898.00 million during the quarter, compared to analysts' expectations of $889.93 million. DENTSPLY SIRONA had a positive return on equity of 20.84% and a negative net margin of 14.99%. The firm's quarterly revenue was down 4.1% compared to the same quarter last year. During the same period in the previous year, the business earned $0.52 earnings per share. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. Equities analysts forecast that DENTSPLY SIRONA Inc. will post 1.39 earnings per share for the current year.

Institutional Investors Weigh In On DENTSPLY SIRONA

Several hedge funds and other institutional investors have recently modified their holdings of XRAY. BlackRock Inc. purchased a new position in DENTSPLY SIRONA during the second quarter valued at approximately $283,405,000. Southpoint Capital Advisors LP purchased a new stake in shares of DENTSPLY SIRONA in the first quarter worth $116,000,000. Armistice Capital LLC boosted its stake in DENTSPLY SIRONA by 27.2% during the fourth quarter. Armistice Capital LLC now owns 7,298,000 shares of the medical instruments supplier's stock valued at $83,416,000 after buying an additional 1,562,000 shares during the period. Invenomic Capital Management LP boosted its stake in DENTSPLY SIRONA by 17.9% during the fourth quarter. Invenomic Capital Management LP now owns 5,132,036 shares of the medical instruments supplier's stock valued at $58,659,000 after buying an additional 780,837 shares during the period. Finally, Edmond DE Rothschild Holding S.A. purchased a new position in DENTSPLY SIRONA during the second quarter worth about $47,780,000. 95.70% of the stock is currently owned by institutional investors.

DENTSPLY SIRONA Company Profile

(Get Free Report)

Dentsply Sirona is a global dental products and technologies company that develops, manufactures and markets solutions for dental professionals, laboratories and patients. Its portfolio includes consumable products, dental equipment and digital technologies used in preventive, restorative, endodontic, orthodontic, implant and prosthetic dentistry.

The company offers dental treatment centers, imaging systems, CAD/CAM systems, intraoral scanners, milling and 3D-printing solutions, instruments, endodontic files and equipment, restorative materials, dental implants, prosthetic components and orthodontic products.

See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in DENTSPLY SIRONA Right Now?

Before you consider DENTSPLY SIRONA, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DENTSPLY SIRONA wasn't on the list.

While DENTSPLY SIRONA currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines